Benzinga | Apr 28, 2021 08:25AM EDT

Vor To Present On VOR33 Manufacturing Scale-Up And Off-Target Editing At ASGCT

Vor Biopharma (NASDAQ:VOR) is pleased to announce that Vor scientists will give two presentations documenting the development, manufacturing, and validation of its engineered hematopoietic stem cell (eHSC) clinical candidate VOR33 at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place virtually May 11-14, 2021.



"As we ready VOR33 for a Phase 1/2a trial, we are pleased to share the first consolidated review of the comprehensive research that underpins this cell therapy candidate and our wider eHSC platform," said John Lydeard, PhD, scientific lead on the VOR33 program and Head of Target Discovery at Vor. "This tremendous progress with Vor's genome engineering process and manufacturing scale-up brings us one step closer to potentially realizing the benefits of our powerful platform to treat patients with acute myeloid leukemia."

The details of the presentations are below:

Oral Presentation

Title: VOR33: A Clinic-Ready CRISPR/Cas9 Engineered Hematopoietic Stem Cell Transplant for the Treatment of Acute Myeloid Leukemia

Presenter: John Lydeard

Session Title: Advances in Ex Vivo Modified Cell Therapies

Session Date/Time: Tuesday May 11, 2021 5:30 PM - 7:15 PM ET

Presentation Time: 7:00-7:15 PM ET

Abstract Number: 7

Poster Presentation

Title: Rigorous Assessment of Off-Target Editing by CRISPR/Cas9 in VOR33, an Engineered Hematopoietic Stem Cell Transplant for the Treatment of Acute Myeloid Leukemia

Session Title: Cell Therapy Product Engineering, Development or Manufacturing

Session Date/Time: Tuesday May 11, 2021 8:00 AM - 10:00 AM ET

Abstract Number: 858